Controversies in the front-line management of chronic lymphocytic leukemia

Leukemia Research

Volumn 32, Issue 5, 2008, Pages 679-688

  Nabhan, Chadi ^a   Shanafelt, Tait D ^b   Kay, Neil E ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukemia; Front line therapy

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEMOGRAPHY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADULT; AGE FACTORS; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 40249091469     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.002     Document Type: Review

References (70)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Binet J.L., Lepoprier M., Dighiero G., et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 40 (1977) 855-864
3. Rai K.R., Sawitsky A., Cronkite E.P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
4. Rai K.R., Peterson B.L., Appelbaum F.R., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
5. Leporrier M., Chevret S., Cazin B., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98 (2001) 2319-2325
6. Zhu Q., Tan D.C., Samuel M., et al. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma 45 (2004) 2239-2245
7. Hillmen P. Beyond detectable minimal residual disease in chronic lymphocytic leukemia. Semin Oncol 33 (2006) S23-S28
8. Catovsky D., Richards S., Matutes E., et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370 (2007) 230-239
9. Eichhorst B.F., Busch R., Hopfinger G., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107 (2006) 885-891
10. Flinn I.W., Neuberg D.S., Grever M.R., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25 (2007) 793-798
11. Robak T., Blonski J.Z., Gora-Tybor J., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood 108 (2006) 473-479
12. Nabhan C., Dyer M.J., and Rosen S.T. Current status of monoclonal antibody therapy for chronic lymphocytic leukemia. Oncology (Williston Park) 17 (2003) 253-262 [discussion 264, 267, passim]
13. Hainsworth J.D., Litchy S., Barton J.H., et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (2003) 1746-1751
14. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
15. Byrd J.C., Murphy T., Howard R.S., et al. Rituximab using a thrice-weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001) 2153-2164
16. O'Brien S.M., Kantarjian H., Thomas D.A., et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001) 2165-2170
17. Williams M.E., Densmore J.J., Pawluczkowycz A.W., et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177 (2006) 7435-7443
18. Huhn D., von Schilling C., Wilhelm M., et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98 (2001) 1326-1331
19. Lin T.S., Lucas M.S., and Byrd J.C. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 30 (2003) 483-492
20. Mone A.P., Cheney C., Banks A.L., et al. Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism. Leukemia 20 (2006) 272-279
21. Nuckel H., Frey U.H., Roth A., et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 514 (2005) 217-224
22. Stanglmaier M., Reis S., and Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 83 (2004) 634-645
23. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99 (2002) 3554-3561
24. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15 (1997) 1567-1574
25. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20 (2002) 3891-3897
26. Lundin J., Kimby E., Bjorkholm M., et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100 (2002) 768-773
27. ®) has superior progression free survival (PFS) vs. chlorambucil as front-line therapy for patients with progressive B-Cell chronic lymphocytic leukemia (BCLL). Blood 108 (2006)
28. Nabhan C., Patton D., Gordon L.I., et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 45 (2004) 2269-2273
29. Faderl S., Thomas D.A., O'Brien S., et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101 (2003) 3413-3415
30. Zent C., Bone N., Call T., et al. Alemtuzumab and rituximab for therapy of patents with early stage high risk CLL: report of a planned interim analysis. Blood 108 (2006)
31. Byrd J.C., Peterson B.L., Morrison V.A., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003) 6-14
32. Byrd J.C., Rai K., Peterson B.L., et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105 (2005) 49-53
33. Del Poeta G., Del Principe M.I., Consalvo M.A., et al. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer 104 (2005) 2743-2752
34. Schulz H., Klein S.K., Rehwald U., et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100 (2002) 3115-3120
35. Keating M.J., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
36. Ferrajoli A., O'Brien S., Wierda W., et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk Lymphoma (2005) 46
37. Keating M.J., Albitar O.B.S., Lerner M., Weirda S., and Kantarjian W. H Extended follow-up of a chemo-immunotherapy regimen FCR as initial therapy for chronic lymphocytic leukemia (CLL). Blood 106 (2005) 599a
38. Kay N.E., Geyer S.M., Call T.G., et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109 (2007) 405-411
39. Shanafelt T.D., Lin T., Geyer S.M., et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 109 (2007) 2291-2298
40. Hallek M. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematol Am Soc Hematol Educ Program (2005) 285-291
41. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23 (2005) 2971-2979
42. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
43. Wendtner C.M., Ritgen M., Schweighofer C.D., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18 (2004) 1093-1101
44. Montillo M., Tedeschi A., Miqueleiz S., et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 2337-2342
45. Del Poeta G., Del Principe M., Maurillo L., et al. Consolidation and maintenance immunotherapy with rituximab improve progression free survival within ZAP-70 positive chronic lymphocytic leukemia (CLL). Blood 108 (2006)
46. Cheson B.D., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
47. Eichhorst B., Busch R., Stauch M., et al. Fludarabine (F) induces higher response rates in first line therapy of older patients (pts) with advanced chronic lymphocytic leukemia (CLL) than chlorambucil: interim analysis of a phase III study of the German CLL Study Group (GCLLSG). Blood 102 (2003)
48. Dreger P., Corradini P., Kimby E., et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21 (2007) 12-17
49. Nabhan C., Coutre S., and Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. Br J Haematol 136 (2007) 379-392
50. Rawstron A.C., Villamor N., Ritgen M., et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21 (2007) 956-964
51. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94 (1999) 1840-1847
52. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999) 1848-1854
53. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1764-1775
54. Del Principe M.I., Del Poeta G., Buccisano F., et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 108 (2006) 853-861
55. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
56. Hamblin T.J., Orchard J.A., Ibbotson R.E., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99 (2002) 1023-1029
57. Ibrahim S., Jilani I., O'Brien S., et al. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 97 (2003) 1914-1919
58. Heintel D., Kienle D., Shehata M., et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 19 (2005) 1216-1223
59. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
60. Juliusson G., and Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 45 (1990) 143-160
61. Juliusson G., Oscier D.G., Fitchett M., et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 323 (1990) 720-724
62. Shanafelt T.D., Jelinek D., Tschumper R., et al. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol 24 (2006) 3218-3219 [author reply 3219-20]
63. Zent C.S., Call T.G., Hogan W.J., et al. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma 47 (2006) 1738-1746
64. Byrd J.C., Gribben J.G., Peterson B.L., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 (2006) 437-443
65. Grever M.R., Lucas D.M., Dewald G.W., et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25 (2007) 799-804
66. Stilgenbauer S.K.A., Busch R., Eichhorst B., Kienle D., Winkler D., Hopfinger G., et al. Dohner H 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: First analysis of genetics in the CLL4 trial of the GCLLSG. Blood 106 (2005) 212a
67. ®) vs. chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL). Blood 108 (2006)
68. Byrd J.C., Lin T.S., Dalton J.T., et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109 (2007) 399-404
69. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24 (2006) 5343-5349
70. Shanafelt T.D., Byrd J.C., Call T.G., et al. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 145 (2006) 435-447